Second-Line Antiretroviral Treatment Successfully Resuppresses Drug-Resistant HIV-1 After First-Line Failure: Prospective Cohort in Sub-Saharan Africa

Little is known about the effect of human immunodeficiency virus type 1 (HIV-1) resistance mutations present at time of regimen switch on the response to second-line anti-retroviral therapy in Africa. In adults who switched to boosted protease inhibitor-based regimens after first-line failure, HIV-R...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2012-06, Vol.205 (11), p.1739-1744
Main Authors: Sigaloff, Kim C. E., Hamers, Raph L., Wallis, Carole L., Kityo, Cissy, Siwale, Margaret, Ive, Prudence, Botes, Mariette E., Mandaliya, Kishor, Wellington, Maureen, Osibogun, Akin, Stevens, Wendy S., van Vugt, Michèle, de Wit, Tobias F. Rinke
Format: Article
Language:English
Subjects:
Adult
Africa South of the Sahara
African art
Anti-HIV Agents - administration & dosage
Antiretroviral Therapy, Highly Active - methods
Antiretrovirals
Arts
Biological and medical sciences
Cohort Studies
Drug resistance
Drug Resistance, Viral
Female
Fundamental and applied biological sciences. Psychology
HIV
HIV 1
HIV Infections - drug therapy
HIV Infections - virology
HIV-1 - drug effects
HIV-1 - isolation & purification
HIV/AIDS
Human immunodeficiency virus 1
Humans
Immunology
Infectious diseases
Male
Medical sciences
Medical treatment failures
Microbiology
Middle Aged
Miscellaneous
Mutation, Missense
Prospective Studies
RNA, Viral - blood
RNA, Viral - genetics
Salvage Therapy - methods
Treatment Outcome
Viral Load
Virology
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Little is known about the effect of human immunodeficiency virus type 1 (HIV-1) resistance mutations present at time of regimen switch on the response to second-line anti-retroviral therapy in Africa. In adults who switched to boosted protease inhibitor-based regimens after first-line failure, HIV-RNA and genotypic resistance testing was performed at switch and after 12 months. Factors associated with treatment failure were assessed using logistic regression. Of 243 participants, 53% were predicted to receive partially active second-line regimens due to drug resistance. The risk of treatment failure was, however, not increased in these participants. In this African cohort, boosted protease inhibitors successfully resuppressed drug-resistant HIV after first-line failure.
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/jis261